A monofocal hydrophilic acrylic IOL with a square-edge design has high capsular biocompatibility
The FDA-approved lens is a single-piece ultraviolet-absorbing posterior chamber IOL intended for the treatment of aphakia. The IOL hydrophilic material, 2-hydroxyethyl methacrylate/methyl methacrylate copolymer (Rayacryl), has a water content of 25.5% in equilibrium. The IOL is available in powers from +8 to +30 D in 0.5-D increments, +30 to 34 D in 1-D increments, and +18 to +23.75 D in 0.75-D increments.
The material allows the IOL to be implanted smoothly and gently with no difficulties.
"The IOL goes into the eye gracefully with no sudden movements and no difficulties unfolding," he said. "To me, it is the perfect compromise between silicone, which tends to unfold rapidly, sometimes in unexpected ways, and the hydrophobic acrylic lenses, the haptics of which tend to get stuck to the optic and do not unfold quickly enough. I like the surgical handling of the [lens]."
Another benefit of the material is its excellent capsular biocompatibility, Dr. Packer said. Once implanted, there is uniform shrinkage of the capsule around the lens, which prevents rotation or movement of the lens anteriorly or posteriorly in the bag.